Efficacy and Safety of Mefloquine, Artesunate, Mefloquine‐Artesunate, and Praziquantel againstSchistosoma haematobium: Randomized, Exploratory Open‐Label Trial | Zendy

Jennifer Keiser | Zendy; Nicaise A. N’Guessan | Zendy; Koffi Daho Adoubryn | Zendy; Kigbafori D. Silué | Zendy; Penelope Vounatsou | Zendy; Christoph Hatz | Zendy; Jürg Utzinger | Zendy; Eliézer K. N’Goran | Zendy

Open Access

Efficacy and Safety of Mefloquine, Artesunate, Mefloquine‐Artesunate, and Praziquantel againstSchistosoma haematobium: Randomized, Exploratory Open‐Label Trial

Author(s) -

Jennifer Keiser,

Nicaise A. N’Guessan,

Koffi Daho Adoubryn,

Kigbafori D. Silué,

Penelope Vounatsou,

Christoph Hatz,

Jürg Utzinger,

Eliézer K. N’Goran

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/651682

Subject(s) - mefloquine , artesunate , medicine , praziquantel , schistosoma haematobium , open label , traditional medicine , pharmacology , schistosomiasis , adverse effect , malaria , immunology , helminths , chloroquine , plasmodium falciparum

Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research